Live feed09:05:00·41dPRReleasevia QuantisnowCastle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026ByQuantisnow·Wall Street's wire, on your screen.CSTL· Castle Biosciences Inc.Health Care
